Eliquis

Eliquis is the brand name for apixaban, a prescription oral anticoagulant marketed by Bristol Myers Squibb in collaboration with Pfizer. It belongs to the direct oral anticoagulant class and works by selectively inhibiting factor Xa, an important component of the blood-clotting process. By reducing factor Xa activity, apixaban decreases the generation of thrombin and thereby lowers the tendency for harmful clots to form. The product became a major branded therapy in cardiovascular medicine after receiving United States Food and Drug Administration approval in 2011. Its initial approved use was to reduce the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation. Subsequent regulatory activity expanded its role in venous thromboembolism care, including treatment of deep vein thrombosis and pulmonary embolism and reduction of the risk of recurrence after initial treatment. In some markets and patient settings, lower-dose tablets are also used for particular prevention indications, subject to the applicable product label. Eliquis is supplied primarily as film-coated tablets in 5 mg and 2.5 mg strengths. The appropriate strength and dosing schedule depend on the indication, kidney function, age, body weight, interacting medicines, and other clinical factors. It is prescription-only and is not interchangeable with other anticoagulants without medical supervision. Like other medicines that inhibit blood clotting, it carries a clinically important risk of bleeding. Official safety information includes warnings concerning serious bleeding and the increased risk of blood clots after premature discontinuation in patients who require anticoagulation. Patients undergoing certain spinal or epidural procedures may also face a risk of spinal or epidural hematoma. The brand is positioned as a modern oral alternative to older anticoagulation approaches that require routine laboratory monitoring or injectable administration in many circumstances. Its commercial significance comes from its use across both atrial-fibrillation stroke prevention and venous thromboembolism treatment and prevention. Bristol Myers Squibb and Pfizer jointly commercialize the medicine in international markets, while regulatory labeling, reimbursement, packaging, and availability vary by country. Eliquis remains an active global prescription brand; its use should be determined by a qualified clinician using the current local prescribing information.

Eliquis is the commercial brand for apixaban, an orally administered factor Xa inhibitor developed and commercialized through a collaboration between Bristol Myers Squibb and Pfizer. The product was created within the development of direct oral anticoagulants, a group of medicines designed to provide predictable anticoagulation through direct action on specific clotting factors. The brand reached an important regulatory milestone in 2011, when the United States approved Eliquis for reducing the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation. This indication addressed a large clinical need because atrial fibrillation can allow clots to form in the heart and subsequently travel to the brain or other organs. The medicine offered an oral factor Xa inhibition approach that did not rely on the same monitoring model as warfarin, although patient selection, dosing, interactions, adherence, and bleeding surveillance remain clinically important. Eliquis subsequently became associated with a broader range of anticoagulation uses. Its labeling includes treatment of deep vein thrombosis and pulmonary embolism, reduction of the risk of recurrent deep vein thrombosis and pulmonary embolism after initial therapy, and selected prevention uses depending on jurisdiction and the applicable prescribing information. The product is available in 5 mg and 2.5 mg tablet strengths, with dosing determined by indication and patient characteristics rather than by brand preference alone. Commercially, Eliquis is jointly associated with Bristol Myers Squibb and Pfizer. Bristol Myers Squibb has been the principal brand owner and commercial organization in the supplied materials, while Pfizer has participated in the global collaboration and commercialization of apixaban. The product is sold internationally, including in the United States and Switzerland, but its exact indications, labeling, reimbursement, and distribution arrangements differ across markets. The brand's medical profile is defined by the balance between prevention of dangerous thrombosis and the risk of bleeding. Official safety information identifies serious or potentially fatal bleeding as a central risk and warns against stopping therapy prematurely when continued anticoagulation is medically required. These considerations, along with renal function, age, body weight, concomitant medicines, and procedural planning, shape clinical use. Eliquis remains an active prescription pharmaceutical brand rather than a consumer health product, and patients are expected to use it under professional supervision.

• 2011

  United States regulatory approval

  [1]Rx ELIQUIS (apixaban) Home Page and Safety Informationeliquis.bmscustomerconnect.com

  Eliquis (apixaban) received United States approval for reducing the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Prescription direct oral anticoagulant for stroke prevention in non-valvular atrial fibrillation and for treatment and prevention of venous thromboembolism

• Prescription anticoagulant · 2011

  Eliquis 5 mg tablets

  The 5 mg film-coated tablet is a principal Eliquis strength used in several approved anticoagulation settings, including stroke and systemic embolism risk reduction in appropriate adults with non-valvular atrial fibrillation and treatment of venous thromboembolism. The correct dose and schedule depend on the approved indication and patient-specific factors. It should be taken only according to the current local prescribing information and a clinician's instructions.

• Prescription anticoagulant · 2011

  Eliquis 2.5 mg tablets

  The 2.5 mg film-coated tablet is used for selected Eliquis dosing regimens and prevention indications when specified by the applicable product label. Dose selection may reflect the treatment phase, the indication, or patient characteristics such as age, body weight, kidney function, and concomitant medicines. Availability and approved uses vary by market.

• 2011

  Launch of Eliquis as an approved apixaban brandProduct launch

  Background

  Bristol Myers Squibb and Pfizer brought apixaban to market under the Eliquis name after United States regulatory approval for a specified atrial-fibrillation stroke-prevention use.

  Action taken

  The partners commercialized prescription Eliquis tablets, initially centered on the 5 mg and 2.5 mg strengths and the approved labeling for non-valvular atrial fibrillation.

  Aftermath

  The brand developed into a broader anticoagulation offering as its approved uses included venous thromboembolism treatment and prevention in relevant patient populations.

  Source

1. 1Rx ELIQUIS (apixaban) Home Page and Safety Informationeliquis.bmscustomerconnect.com